SLNCF
Silence Therapeutics plcBS score 32.4LOWPHASE2 · mkt cap $283.4M · rev ttm $559.0K
drug hypothesis
SLN124 modulates Not provided in available filing content to treat Not specified - trial conducted in healthy volunteers (n=24), no disease indication disclosed.
moa:Not provided in available filing content
score breakdown
trial design20
base rate disconnect11
language red flags100
composite32.4
valuation analysis
market cap$283.4M
revenue ttm$559.0K
phasePHASE2
historical base rate15%
disconnect ratio0.4x
lead trialNCT05537571
meta
cik0001479615
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, PK and PD of SLN124 in 24 healthy volunteers. Secondary endpoints include pharmacokinetic parameters: Cmax, AUC, and apparent total clearance (CL/F).
primary endpoint:Incidence of treatment-emergent adverse events (8 weeks)
claimed differentiation
Not provided in available filing content
language red flags
- SEC filing business section content not provided - only placeholder '4' visible
- No target, mechanism of action, or indication disclosed in available data
- No preclinical evidence or differentiation claims included in provided content
- No stated risks or catalysts provided
- Clinical trial data is for Phase 1 in healthy volunteers only - extremely early stage with no efficacy data